Third Rock Ventures Amends Tango Therapeutics Stake
Ticker: TNGX · Form: SC 13D/A · Filed: Sep 4, 2024 · CIK: 1819133
Sentiment: neutral
Topics: schedule-13d, amendment, ownership-change
Related Tickers: TGTX
TL;DR
Third Rock Ventures filed an update on their Tango Therapeutics holdings. Watch for potential moves.
AI Summary
Third Rock Ventures IV, L.P. filed an amendment (No. 1) to its Schedule 13D on August 30, 2024, regarding its holdings in Tango Therapeutics, Inc. The filing indicates a change in the beneficial ownership of Tango Therapeutics' common stock. Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC are also listed as group members in this filing.
Why It Matters
This amendment signals a potential shift in the ownership structure or strategy of Tango Therapeutics, which could impact its stock price and future corporate actions.
Risk Assessment
Risk Level: medium — Amendments to Schedule 13D filings often indicate changes in significant shareholder positions, which can lead to increased volatility.
Key Players & Entities
- Third Rock Ventures IV, L.P. (company) — Filing entity
- Tango Therapeutics, Inc. (company) — Subject company
- Third Rock Ventures GP IV, L.P. (company) — Group member
- TRV GP IV, LLC (company) — Group member
- Kevin Gillis (person) — Authorized contact
FAQ
What specific changes in beneficial ownership are detailed in this amendment?
The filing is an amendment (No. 1) to a Schedule 13D, indicating a change in beneficial ownership, but the specific details of the change are not provided in the header information.
Who are the primary entities involved in this filing?
The primary entities are Third Rock Ventures IV, L.P. (the filer), Tango Therapeutics, Inc. (the subject company), and group members Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC.
When was this amendment filed?
This amendment was filed as of date 20240904, with the date of the event being August 30, 2024.
What is the CUSIP number for Tango Therapeutics, Inc. common stock?
The CUSIP number for Tango Therapeutics, Inc. common stock is 87583X109.
What was the former company name for Tango Therapeutics, Inc.?
The former company name for Tango Therapeutics, Inc. was BCTG Acquisition Corp., with a date of name change on 20200723.
Filing Stats: 1,464 words · 6 min read · ~5 pages · Grade level 11.2 · Accepted 2024-09-04 20:45:40
Key Financial Figures
- $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value (Class of Securities) 875
Filing Documents
- d857596dsc13da.htm (SC 13D/A) — 73KB
- 0001193125-24-213369.txt ( ) — 74KB
(a)-(c) is hereby amended and restated as follows
Item 5(a)-(c) is hereby amended and restated as follows: (a) As of August 30, 2024, TRV IV had shared voting and dispositive power with respect to 17,001,475 shares of the Issuers Common Stock, constituting approximately 15.9% of the Issuers outstanding Common Stock. As of August 30, 2024, Third Rock Ventures GP IV, L.P. ( TRV GP IV ), as the general partner of TRV IV may be deemed to have shared voting and dispositive power with respect to all 17,001,475 shares of the Issuers Common Stock owned by TRV IV, constituting approximately 15.9% of the Issuers outstanding Common Stock. As of August 30, 2024, TRV GP IV, LLC ( TRV GP IV LLC , and collectively with TRV IV and TRV GP IV, the Reporting Persons ), as the general partner of TRV GP IV may be deemed to have shared voting and dispositive power with respect to all 17,001,475 shares of the Issuers Common Stock owned by TRV IV, constituting approximately 15.9% of the Issuers outstanding Common Stock. The percent of class was calculated based on 107,144,465 shares of common stock issued and outstanding as of August 1, 2024, as disclosed in the Issuers 10-Q filed with the Securities and Exchange Commission on August 7, 2024. (b) Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets (c) Except as set forth in the table below, no transactions in the Common Stock were effected by the Reporting Persons during the 60-day period ended August 30, 2024. Date Amount of Securities Price per Share Where and How Effected TRV IV 07/17/2024 550,171 $ 9.7903 * Disposed in the Open Market TRV IV 07/18/2024 191,490 $ 9.8098 Disposed in the Open Market TRV IV 07/2